Skip to main content
SpringerLink
Log in

Fettstoffwechsel und Hypertonie bei Diabetes

  • Chapter
Diabetologie kompakt

  • 6885 Accesses

Zusammenfassung

Fettstoffwechselstörungen spielen eine zentrale Rolle in der Entwicklung von Gefäßkomplikationen bei Patienten mit Diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Abschn. 7.1

  • Booth GL, Kapral MK, Fung K et al. (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population- based retrospective cohort study. Lancet 368: 29–36

    Google Scholar 

  • Bosch J, Gerstein HC, Dagenais GR et al. (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367: 309–318

    Google Scholar 

  • Brunzell JD, Davidson M, Furberg CD et al. (2008) Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811–822

    Google Scholar 

  • Catapano AL, Reiner Z, De Backer G et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217 Suppl 1: S1–44

    Google Scholar 

  • Drew BG, Rye KA, Duffy SJ et al. (2012) The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 8: 237–245

    Google Scholar 

  • Grundy SM, Cleeman JI, Merz CN et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239

    Google Scholar 

  • Jun M, Foote C, Lv J et al. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875–1884

    Google Scholar 

  • Kearney PM, Blackwell L, Collins R et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–-125

    Google Scholar 

  • Parhofer KG (2011) Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clin Lipidol 6: 401–411

    Google Scholar 

  • Parhofer KG, Barrett PH (2006) Thematic review series: patientoriented research. What we have learned about VLDL and LDL metabolism from human kinet ics studies. J Lipid Res 47: 1620–1630

    Google Scholar 

  • Sattar N, Preiss D, Murray HM et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomi sed statin trials. Lancet 375: 735–742

    Google Scholar 

  • Sorrentino SA, Besler C, Rohrer L et al. (2010) Endothelialvasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release nia cin therapy. Circulation 121: 110–-122

    Google Scholar 

  • Varbo A, Benn M, Tybjaerg-Hansen A et al. (2013) Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61:427-436 Literatur zu Abschn. 7.2

    Google Scholar 

Literatur zu Abschn. 7.2

  • ACC/AHA (2013) A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. http://content.onlinejacc.org/article.aspx?articleid=1770217. doi:10.1016/j. jacc.2013.11.002

  • DGE (2013) Deutsche Gesellschaft für Endokrinologie. Pressemitteilung der DGE vom 15.11.13. Neue US-Leitlinie zu Herz-Kreislauf-Erkrankungen: DGE sieht Verzicht auf Cholesterinzielwerte kritisch. Pressemitteilung der http://www.endokrinologie.net/presse_131115.php. Zugriff 24 Feb 2013

Literatur zu Abschn. 7.3

  • ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585

    Google Scholar 

  • ADVANCE Collaborative Group, Patel A (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829–840. doi:10.1016/S0140-6736(07)61303-61308

    Google Scholar 

  • Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB,Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15): 1393–1401

    Google Scholar 

  • Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489): 895–906

    Google Scholar 

  • ESH/ESC (2013) ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 31: 1281–1357

    Google Scholar 

  • Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18): 2227–2236

    Google Scholar 

  • Jamerson K, Weber MA, Bakris GL et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med 359: 2417–2428

    Google Scholar 

  • Krone W, Böhm M (2004) Diabetes mellitus needs unrestricted evaluation of patient data to yield treatment progress. The DUTY Register. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 47(6): 540–546

    Google Scholar 

  • Novartis (2011) Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in high-risk patients with diabetes and renal impairment. http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml. Zugriff 29 April 2014

  • ONTARGET Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559

    Google Scholar 

  • Patel A, MacMahon S, Chalmers J et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829–840

    Google Scholar 

  • Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373(9677): 1765–1772

    Google Scholar 

  • Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1). doi: 10.1136/bmjopen- 2012-001986

    Google Scholar 

  • Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group (2001) Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344(1): 3–10

    Google Scholar 

  • Vondracek E, Renn W, Weger B, Mahfoud F, Jacob S (2013) Aktuelle Versorgungsdaten aus dem T2Day2.0-Screening: Wie häufig ist die therapierefraktäre Hypertonie bei Menschen mit Diabetes mellitus Typ 2(DM)? Diabetologie Stoffwechsel 8–P227. DOI: 10.1055/s-0033-1341887

    Google Scholar 

  • Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J; ADVANCE Collaborative Group, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes. Diabetes Care 32(11): 2068–2074

    Google Scholar 

Literatur zu Abschn. 7.4

  • ESH (2013) European Society of Hypertension. 23rd European Meeting on Hypertension & Cadiovascular Protection 2013 in Mailand. http://www.esh2013.org. Zugriff 24 Feb 2014

  • Bhatt DL, Kandzari DE, O‹Neill WW et al. (2014) A controlled trial of renal denervation for resistant hypertension. New Engl J Med 370: 1393–1401

    Google Scholar 

Literatur zu Abschn. 7.5

  • ADA (2013) American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 36 (Suppl 1): S11–66

    Google Scholar 

  • ALLHAT (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997

    Google Scholar 

  • Bakris GL (2013) Treatment of hypertension in patients with diabetes mellitus. www.upto date.com, last accessed July 29th 2013

    Google Scholar 

  • Boden WE, Probstfield JL, Anderson T et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255–2267

    Google Scholar 

  • Colhoun HM, Betteridge DJ, Durrington PN et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685–696

    Google Scholar 

  • Cushman WC, Evans GW, Byington RP et al. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585

    Google Scholar 

  • Ginsberg HN, Elam MB, Lovato LC et al. (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574

    Google Scholar 

  • Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762

    Google Scholar 

  • Jamerson K, Weber MA, Bakris GL et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med 359: 2417–2428

    Google Scholar 

  • Kearney PM, Blackwell L, Collins R et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–125

    Google Scholar 

  • Lindholm LH, Ibsen H, Dahlof B et al. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004–1010

    Google Scholar 

  • Patel A, MacMahon S, Chalmers J et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829–840

    Google Scholar 

  • Reiner Z, Catapano AL, De Backer G et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32: 1769–818

    Google Scholar 

  • Säly CH, Drexel V, Vonbank A, Drexel H (2011) Combination lipid therapy for type 2 diabetes patients. Therapy 8: 129–141

    Google Scholar 

  • Shepherd J, Barter P, Carmena R et al. (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29: 1220–1226

    Google Scholar 

  • Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith Jr SC, Levy D, Watson K, Wilson PWF (2013) ACC/ AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. doi: 10.1161/01.cir.0000437738.63853.7a 11/2013

    Google Scholar 

  • UKPDS (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (Clinical research ed) 317: 703–713

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. für Innere Medizin, Landeskrankenhaus Feldkirch VIVIT Institut, Carina Gasse 47, A-6807, Feldkirch, Österreich

    Prof. Dr. med. H. Drexel

  2. Praxis für Prävention und Therapie, Brombeerweg 6, 78048, Villingen-Schwenningen

    Prof. Dr. med. S. Jacob

  3. Klinikum der Universität München Medizinische Klinik II – Großhadern, Marchioninistr. 15, 81377, München

    Prof. Dr. med. K. G. Parhofer

  4. Akademisches Lehrkrankenhaus Feldkirch Abt. für Innere Medizin und Kardiologie VIVIT Institut, Carinagasse 47, A-6800, Feldkirch, Österreich

    Priv.-Doz. Dr. med. C. Säly

  5. Universitätsklinikum Bergmannsheil Ruhr-Universität Bochum, Bürkle de la Camp-Platz 1, 44789, Bochum

    Prof. (em.) Dr.med. Dr. h.c. H. Schatz

  6. Akademisches Lehrkrankenhaus Feldkirch Abt. für Innere Medizin und Kardiologie VIVIT Institut, Carinagasse 47, A-6800, Feldkirch, Österreich

    A. Vonbank PhD

Authors
  1. Prof. Dr. med. H. Drexel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. S. Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. K. G. Parhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Priv.-Doz. Dr. med. C. Säly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. (em.) Dr.med. Dr. h.c. H. Schatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Vonbank PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Bergmannsheil Ruhr-Universität Bochum, Bochum

    Helmut Schatz

  2. Charité – Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin

    Andreas F. H. Pfeiffer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Drexel, H., Jacob, S., Parhofer, K., Säly, C., Schatz, H., Vonbank, A. (2014). Fettstoffwechsel und Hypertonie bei Diabetes. In: Schatz, H., Pfeiffer, A. (eds) Diabetologie kompakt. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41358-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-41358-2_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-41357-5

  • Online ISBN: 978-3-642-41358-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation